Bimatoprost-induced chemical blepharoplasty.
We report significant changes in the appearance of the periorbital area, beyond eyelash enhancement, induced by the topical application of bimatoprost ophthalmic solution, 0.03% (Latisse®, Allergan, Inc., Irvine, CA). To our knowledge, this is the first report in the dermatology or plastic surgery literature describing the rejuvenating effect and overall improvement in the appearance of the periorbital area resulting from applying Latisse to the upper eyelid margins. To date, reports in the literature discuss side-effects and potential complications of topical bimatoprost therapy causing a constellation of findings known as PAP (prostaglandin-associated periorbitopathy). While periorbitopathy implies pathology or a state of disease, we report changes that can be perceived as an improvement in the overall appearance of the periorbital area. We, therefore, propose a name change from PAP to PAPS - prostaglandin- associatedperiorbital syndrome. This better describes the beneficial, as well as the possible negative effects of topical bimatoprost. Although there is a risk for periorbital disfigurement, when used bilaterally, in properly selected candidates and titrated appropriately, bimatoprost can be beneficial. The striking improvement in the appearance of some individuals warrants further research into the potential use of topical bimatoprost to achieve a "chemical blepharoplasty."
Deborah S
DS
Sarnoff
Robert H
RH
Gotkin
D000287:Administration, Topical; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000069580:Bimatoprost / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D019882:Blepharoplasty / Q000379:methods*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009883:Ophthalmic Solutions; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D000069580:Bimatoprost